We’re allowed. It’s Friday.
Nailing Jell-O To A Wall
Baron Receives Tysabri
The Associated Press reports this morning that Fred Baron received Biogen’s drug Tysabri to use as an experimental treatment for multiple myeloma “after a ‘legal basis’ for its use was found.”
We’re not quite sure what the legal obstacle might have been, but we wish both Baron and Biogen the best.
Bextra and Celebrex Cases Settled
We don’t know any more than what we’ve read at Pharmalot, but the post there suggests that Pfizer has settled essentially all Bextra and Celebrex personal injury cases, along with the state attorney general cases and the consumer fraud class actions.
Fred Baron and Compassionate Use
Off-Label Use – Yet Again
Enough things – well, three, anyway – about off-label use have piled up in our inbox to warrant yet another point of the subject. In case anybody has forgotten, our basic views about off-label use are: (1) on the whole, it’s far more medically beneficial than not and often represents the medical standard of care;
The End Of Securities Fraud Class Actions, Part II
We posted a couple of weeks ago about Professor Adam Pritchard’s proposal to amend corporate articles of incorporation to waive the fraud-on-the-market presumption of reliance in securities fraud cases. That would basically eliminate securities class action lawsuits against companies that adopted the amendment (prospectively — from the date the amendment was adopted).
Securities Docket has
A Final MDL Timing Issue
Okay, you caught us.
We did a series of posts about multidistrict litigation last month, including this MDL compendium and this post about predicting how long the MDL Panel will take to decide motions.
In the latter of those two posts, we deftly avoided one issue. (No — we didn’t “sluff” it; we “deftly avoided”
Friend of the Court Briefs in Gunvalson v. PTC
Cert. Granted In McDarby
McDarby and Cona v. Merck was the New Jersey state appellate decision that came down in May and addressed a half dozen issues that concern readers of this blog. Among other things, McDarby held that plaintiffs could not pursue personal injury product liability claims under the New Jersey Consumer Fraud Act and that a New